{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:08:46Z","timestamp":1789016926555,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021515","name":"Sanofi Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clml.2024.02.004","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T17:33:10Z","timestamp":1707759190000},"page":"358-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdeep","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.02.004_bib0001","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.3390\/cancers13205154","article-title":"Relapsed\/refractory multiple myeloma in 2020\/2021 and beyond","volume":"13","author":"Podar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.02.004_bib0002","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.02.004_bib0003","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.02.004_bib0004","unstructured":"Maples KT, Johnson C, Lonial S. Antibody treatment in multiple myeloma. Clin Adv Hematol Oncol. 2021;19:166-174."},{"key":"10.1016\/j.clml.2024.02.004_bib0005","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2024.02.004_bib0006","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2024.02.004_bib0007","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2024.02.004_bib0008","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2024.02.004_bib0009","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.02.004_bib0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.02.004_bib0011","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.02.004_bib0012","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"Suppl.2","key":"10.1016\/j.clml.2024.02.004_bib0013","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S2152-2650(23)01615-4","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis","volume":"23","author":"Yong","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 16","key":"10.1016\/j.clml.2024.02.004_bib0014","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1200\/JCO.2023.41.16_suppl.8029","article-title":"Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: updated results from the Phase 3 IKEMA study","volume":"41","author":"Facon","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2024.02.004_bib0015","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/S2152-2650(23)01905-5","article-title":"Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and\/or refractory multiple myeloma in real life context in France: IMAGE subgroup analysis based on subgroups of interest","volume":"23","author":"Decaux","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.02.004_bib0016","unstructured":"Sarclisa (isatuximab) [prescribing information]: Sanofi; July 2022. Accessed: December 6, 2023. Available at: https:\/\/products.sanofi.us\/Sarclisa\/sarclisa.pdf."},{"key":"10.1016\/j.clml.2024.02.004_bib0017","unstructured":"European Medicines Agency. Sarclisa, INN-Isatuximab. Summary of product characteristics. 2021. Accessed: December 6, 2023. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sarclisa-epar-product-information_en.pdf."},{"key":"10.1016\/j.clml.2024.02.004_bib0018","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.02.004_bib0019","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","article-title":"Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation","volume":"37","author":"Ocio","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.02.004_bib0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.02.004_bib0021","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines, multiple myeloma. Version 1.2024. Accessed: December 6, 2023. Available at: https:\/\/www.nccn.org."},{"key":"10.1016\/j.clml.2024.02.004_bib0022","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2217\/fon-2019-0368","article-title":"Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics","volume":"15","author":"Anderson","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2024.02.004_bib0023","first-page":"E38","article-title":"Administration of subcutaneous monoclonal antibodies in patients with cancer","volume":"46","author":"Rodrigues Ferreira","year":"2019","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.clml.2024.02.004_bib0024","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.02.004_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11596-018-1844-y","article-title":"Subcutaneous versus intravenous bortezomib administration for multiple myeloma patients: a meta-analysis","volume":"38","author":"Mu","year":"2018","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.clml.2024.02.004_bib0026","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.02.004_bib0027","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00432-020-03365-w","article-title":"Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results","volume":"147","author":"Usmani","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2024.02.004_bib0028","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.breast.2022.03.001","article-title":"Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: final results of the SafeHER study","volume":"64","author":"Gligorov","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.clml.2024.02.004_bib0029","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.annonc.2023.05.009","volume":"34","author":"Burotto","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2024.02.004_bib0030","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2024.02.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261336","article-title":"Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma","volume":"17","author":"Harvey","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2024.02.004_bib0032","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.02.004_bib0033","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12325-021-01996-0","article-title":"White paper on the value of time savings for patients and healthcare providers of breast cancer therapy: the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection as an example","volume":"39","author":"Jackisch","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2024.02.004_bib0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40259-023-00626-1","article-title":"Advancing subcutaneous dosing regimens for biotherapeutics: clinical strategies for expedited market access","volume":"38","author":"Bittner","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.clml.2024.02.004_bib0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41669-022-00361-3","article-title":"A Systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting","volume":"7","author":"McCloskey","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.clml.2024.02.004_bib0036","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1002\/cam4.5160","article-title":"Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: final results of the non-interventional study MabSCale","volume":"12","author":"D\u00fcrig","year":"2023","journal-title":"Cancer Med"},{"issue":"Suppl 16","key":"10.1016\/j.clml.2024.02.004_bib0037","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1200\/JCO.2022.40.16_suppl.8025","article-title":"Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed\/refractory multiple myeloma (RRMM): interim phase 1b study results","volume":"40","author":"Quach","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2024.02.004_bib0038","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1182\/blood-2022-166840","article-title":"Subcutaneous isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma: phase 1b expansion study results","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2024.02.004_bib0039","first-page":"S206","article-title":"Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide-dexamethasone in relapsed\/refractory multiple myeloma (RRMM)","volume":"23","author":"Quach","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.02.004_bib0040","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2217\/imt-2022-0097","article-title":"Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump","volume":"14","author":"Wasserman","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clml.2024.02.004_bib0041","unstructured":"A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and\/or refractory multiple myeloma (RRMM). NCT05405166. Accessed: December 6, 2023. Available at: ClinicalTrials.gov: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05405166."},{"key":"10.1016\/j.clml.2024.02.004_bib0042","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1038\/s41375-021-01262-w","article-title":"Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed\/refractory multiple myeloma","volume":"35","author":"Usmani","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.02.004_bib0043","doi-asserted-by":"crossref","first-page":"e829","DOI":"10.1097\/HS9.0000000000000829","article-title":"Phase 1b study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed, transplant-ineligible multiple myeloma patients","volume":"7","author":"Ocio","year":"2023","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.02.004_bib0044","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1182\/blood-2023-175020","article-title":"30-min infusion of isatuximab in newly diagnosed multiple myeloma (NDMM) patients: Results of a Phase 1b study","volume":"142","author":"Ocio","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.02.004_bib0045","unstructured":"Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) \u2013 Master Protocol. NCT04643002. Accessed: December 6, 2023. Available at: ClinicalTrials.gov: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04643002."},{"key":"10.1016\/j.clml.2024.02.004_bib0046","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10549-020-05604-7","article-title":"Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer","volume":"181","author":"Denys","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clml.2024.02.004_bib0047","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s12325-023-02477-2","article-title":"Efficacy, safety, patient experience, and tolerability of risankizumab administered by on-body injector for moderate to severe Crohn's disease","volume":"40","author":"Loftus","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2024.02.004_bib0048","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12883-023-03190-x","article-title":"Assessment of the treating physicians' first-hand experience with handling and satisfaction of ofatumumab therapy: findings from the PERITIA survey conducted in Europe","volume":"23","author":"Rau","year":"2023","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clml.2024.02.004_bib0049","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/JAA.S358738","article-title":"AIRE Group. Reliability, satisfaction and effectiveness of benralizumab home self-administration in patients with severe eosinophilic asthma in real-world practice: the Auto-Benra study","volume":"15","author":"Garc\u00eda-Moguel","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.clml.2024.02.004_bib0050","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.936162","article-title":"Long-term effectiveness, safety, and patient-reported outcomes of self-administered subcutaneous hepatitis B immunoglobulin in liver post-transplant hepatitis B prophylaxis: a prospective non-interventional study","volume":"27","author":"Roche","year":"2022","journal-title":"Ann Transplant"},{"key":"10.1016\/j.clml.2024.02.004_bib0051","doi-asserted-by":"crossref","first-page":"e19012","DOI":"10.1097\/MD.0000000000019012","article-title":"Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study","volume":"99","author":"Ch\u00e9rin","year":"2020","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T13:02:46Z","timestamp":1716987766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2152265024000636"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}